ConductScience.org, home

Paper42469396

Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.

Maffini E and 25 others. Bone Marrow Transplant, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Papers, record 42469396. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42469396

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.
PubMed
Journal
Bone Marrow Transplant
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-11-05
PubMed

Authors26

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Maffini EEnricohttps://orcid.org/0000-0001-7356-2328
2Ngoya MMaudhttps://orcid.org/0000-0002-7810-6900
3Houhou MMohamed
4Benakli MMalekhttps://orcid.org/0000-0001-8444-890X
5Bahar BBabak
6Aljurf MMahmoudhttps://orcid.org/0000-0003-3942-7370
7Halahleh KKhalidhttps://orcid.org/0000-0002-1161-9138
8Peffault de Latour RRegis
9Blau IWIgor-Wolfgang
10Clark AAndrew
11Flynn CCatherine
12Remenyi PPPeter Pal
13Maroto MLMaria Losa
14Yakoub-Agha IIbrahimhttps://orcid.org/0000-0003-4524-8782
15Sengeloev HHenrik
16Castilla-Llorente CCristinahttps://orcid.org/0000-0002-7728-5804
17Nicholson EEmmahttps://orcid.org/0000-0002-6439-0795
18Salmenniemi UUrpu
19Vrhovac RRadovanhttps://orcid.org/0000-0003-3323-3487
20Passweg JJakobhttps://orcid.org/0000-0001-7092-3351

Source PubMed

See all 26 authorsDownload CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Transplantation ConditioningMajor topic
Leukemia, Myeloid, AcuteMajor topic
Hematopoietic Stem Cell TransplantationMajor topic
Humans
Adult
Female
Male
Retrospective Studies
Young Adult
Adolescent
Remission Induction
Treatment Outcome

Source PubMed

Download CSV of topics

References52

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
124065243Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.Blood2013https://conductscience.org/library/papers/24065243PubMed
223129746Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.J Clin Oncol2013https://conductscience.org/library/papers/23129746PubMed
327927772
Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Haematologica2017https://conductscience.org/library/papers/27927772PubMed
433730842Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend "when and for whom" in 2021?Haematologica2021https://conductscience.org/library/papers/33730842PubMed
527916512
Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation.
Biol Blood Marrow Transplant2017https://conductscience.org/library/papers/27916512PubMed
629550381Conditioning intensity in HCT for AML: the jury is still out.Lancet Haematol2018https://conductscience.org/library/papers/29550381PubMed
736460819
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT.
Bone Marrow Transplant2023https://conductscience.org/library/papers/36460819PubMed
824081656Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation.Blood2013https://conductscience.org/library/papers/24081656PubMed
924804873Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: a survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Cancer2014https://conductscience.org/library/papers/24804873PubMed
1039440198Long-term outcome of 2-year survivors after allogeneic hematopoietic cell transplantation for acute leukemia.Hemasphere2024https://conductscience.org/library/papers/39440198PubMed
1128638379Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.Front Immunol2017https://conductscience.org/library/papers/28638379PubMed
1235172507Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission.JCO Precis Oncol2017https://conductscience.org/library/papers/35172507PubMed
1338197938Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML.Blood Adv2024https://conductscience.org/library/papers/38197938PubMed
1410627126
Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia.
Blood1999https://conductscience.org/library/papers/10627126PubMed
1537746158
Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT.
Hemasphere2023https://conductscience.org/library/papers/37746158PubMed
1636150050Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies.Blood Adv2022https://conductscience.org/library/papers/36150050PubMed
1738225386Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study.Bone Marrow Transplant2024https://conductscience.org/library/papers/38225386PubMed
1830165887
Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine.
J Hematol Oncol2018https://conductscience.org/library/papers/30165887PubMed
199463096Acute and delayed toxicities of total body irradiation. Seattle Marrow Transplant Team.Int J Radiat Oncol Biol Phys1983https://conductscience.org/library/papers/9463096PubMed
2029550384
Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial.
Lancet Haematol2018https://conductscience.org/library/papers/29550384PubMed

See all 52 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42469396

GET https://conductscience.org/api/papers/v1/42469396/authors?page=2